AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Impact of Ezetimibe on Statin for the Prevention of Stroke and New-Onset Diabetes Mellitus in Patients with Atrial Fibrillation: A Nationwide Investigation

By Lee K, kim J, Kim C et al.

Introduction: Statin therapy is standard for the prevention of atherosclerotic cardiovascular disease. However, the safety of high-intensity statin therapy remains debatable, including the potential risk of new-onset diabetes mellitus (NODM). Since ezetimibe provides an additional lipid-lowering effect, the combination with a lower statin dose may offer comparable stroke prevention and improves safety in patients with atrial fibrillation (AF). Purpose: The study aimed to evaluate the efficacy and safety of statin/ezetimibe combination therapy compared to high-intensity statin monotherapy in a nationwide AF cohort. Methods: The analysis included a total of 644,811 patients with new-onset AF from the Korean National Health Insurance Service database. The primary endpoint was the 10-year incidence of net adverse clinical and cerebral events (NACCE), defined as a composite of stroke, acute coronary syndrome (ACS), major bleeding, and all-cause mortality. Risks were estimated using Cox hazards models, and inverse probability weighting was applied to reduce confounding. Results: In comparison with low-intensity statins, moderate-to-high intensity statin therapy demonstrated a significantly lower risk of NACCE (HR 0.919, 95% CI 0.848-0.997; p = 0.042), with a greater reduction when combined with ezetimibe (HR 0.877, 95% CI 0.800-0.963; p = 0.006). Only high-intensity statin therapy was associated with an increased risk of NODM (HR 1.253, 95% CI 1.083-1.449; p = 0.024). In direct comparison, moderate-intensity statin/ezetimibe combination therapy was associated with lower risks of NACCE (HR 0.894, 95% CI 0.845-0.945; p < 0.001) and NODM (HR 0.702, 95% CI 0.627-0.786; p < 0.001) than high-intensity monotherapy. No significant differences were observed for ischemic stroke (HR 0.926, 95% CI 0.834-1.028; p = 0.150), major bleeding (HR 0.913, 95% CI 0.752-1.108; p = 0.358), and all-cause mortality (HR 1.018, 95% CI 0.934-1.108; p = 0.691). Conclusion: In this nationwide AF cohort, moderate-intensity statin/ezetimibe combination therapy was associated with lower risks of NACCE and NODM than high-intensity statin monotherapy, with comparable risks of stroke, bleeding, and mortality. These findings suggest that the synergistic effect of ezetimibe co-administration could permit a reduction in statin intensity, thereby potentially mitigating statin-related adverse events without compromising stroke prevention.

doi.org/10.1161/circ.154.suppl_1.5868Interventions

AgingResearch.News